1. Signaling Pathways
  2. GPCR/G Protein
    Neuronal Signaling
  3. Cannabinoid Receptor
  4. Cannabinoid Receptor Inhibitors

Cannabinoid Receptor Inhibitors

CB1

CB2

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.

Cannabinoid Receptor Inhibitors, Agonists, Antagonists, Activators & Modulators
Product Name CB1 CB2 Purity
Rimonabant Hydrochloride
CB1 , Ki: 1.8 nM
  99.95%
Pregnenolone
CB1
  99.87%
JD-5037
CB1 , IC50: 1.5 nM
  98.05%
Isopropyl dodec-11-enylfluorophosphonate
CB1 , IC50: 2 μM
 
SR144528  
CB2
99.25%
Pregnenolone monosulfate sodium
CB1
 
Rimonabant
CB1 , Ki: 1.8 nM
  99.41%
Leelamine
CB1
CB2
98.36%
Yangonin
CB1 , IC50: 1.79 μM
CB1 , Ki: 0.72 μM
  99.79%
AM281
CB1 , IC50: 9.91 nM
CB2 , IC50: 13000 nM
≥99.0%
CB1 antagonist 4
CB1
  99.00%
GW-405833
CB1 , EC50: 16.1 μM
CB2 , EC50: 50.7 nM
99.12%
Etrinabdione  
CB2
98.56%
Pregnenolone monosulfate
CB1
  99.22%
Leelamine hydrochloride
CB1
  99.06%
N-Oleoyl glycine
CB1
  ≥99.0%
Tedalinab  
CB2
99.94%
Bay 59-3074
CB1 , Ki: 48.3 nM
CB2 , Ki: 45.5 nM
99.00%
GAT211
CB1
  99.98%
CB2R PAM  
cannabinoid type-2 receptors
98.46%
Tetrahydromagnolol
CB1 , EC50: 9010 nM
CB1 , Ki: 2260 nM
CB2 , EC50: 170 nM
CB2 , Ki: 416 nM
99.79%
AZD1940
hCB1-R, pKi: 7.93
hCB2-R, pKi: 9.06
99.45%
SCH 336  
hCB2-R
98.85%
CB2 modulator 1  
CB2
99.02%
CB1/2 agonist 3
hCB1-R, Ki: 5.9 nM
hCB2-R, Ki: 3.5 nM
99.83%
RVD-Hpα TFA
CB1
  99.32%
Auriculasin
CB1 , IC50: 8.92 μM
  98.58%
Noladin ether
CB1 , Ki: 21.2 nM
CB2 , Ki: >3 mM
≥98.0%
Drinabant
hCB1-R, IC50: 25 nM
rCB1-R, IC50: 10 nM
CB2 , IC50: 10000 nM
≥99.0%
CB2R/FAAH modulator-3
CB1 , Ki: 67.6 nM
CB2 , Ki: 20.1 nM
99.71%
PGN36  
cannabinoid type-2 receptors, Ki: 0.09 μM
CB2R antagonist 3  
CB2R
CB1/2 agonist 1
hCB1-R, EC50: 56.15 nM
cannabinoid type-2 receptors, EC50: 11.63 nM
99.20%
Zevaquenabant
CB1
 
AM9405
CB1 , IC50: 45.71 nM
 
ANEB-001
CB1
 
PSNCBAM-1
hCB1-R, EC50: 0.1 μM
 
(R)-SLV 319
CB1 , Ki: 894 nM
 
RTICBM-189
CB1 , pIC50: 7.54
hCB1, pIC50: 5.29
mCB1, pIC50: 6.25
  99.73%
LY320135
CB1 , Ki: 141 nM
CB2 , Ki: >10 μM
O-2050
CB1 , Ki: 2.5 nM
CB2 , Ki: 0.2 nM
Tocrifluor 1117
CB1
 
CB1R Allosteric modulator 4
hCB1-R
 
hBChE-IN-2  
hCB2-R, IC50: 0.78 μM
BAY 38-7271
CB1 , Ki: 1.85 nM
CB2 , Ki: 5.96 nM
CB2R-IN-1  
CB2 , Ki: 0.9 nM
CB1R Allosteric modulator 3
CB1
  98.05%
CB2R agonist 3  
CB2R, EC50: 0.37 μM
CB2 receptor agonist 2  
CB2 , Ki: 8.5 nM
CBR Agonist-2
hCB1-R, EC50: 960 nM
hCB1-R, Ki: 970 nM
 
CB2R probe 1  
cannabinoid type-2 receptors, Ki: 130 nM
GW 833972A  
hCB2-R, pEC50: 7.3
rat CB2-R, pEC50: 7.5
CB2R/FAAH modulator-2
CB1 , Ki: 152.9 nM
CB2 , Ki: 10.8 nM
CB2R agonist 1  
CB2R, EC50: 0.56 μM
CB1R antagonist 1
hCB1-R, IC50: 4.2 μM
hCB1-R, EC50: 10 μM
  99.89%
CB1 inverse agonist 2
CB1 , pKi: 9.7
CB2 , pKi: 6.0
2-Palmitoylglycerol
CB1
  ≥99.0%
rel-O-2050
CB1
 
CB2R/FAAH modulator-1
CB1R, Ki: 241.3 nM
CB1R, EC50: 489 nM
CB2R, Ki: 14.8 nM
CB2R, EC50: 123.6 nM
CB1/2 agonist 2
hCB1-R, Ki: 3.5 nM
hCB2-R, Ki: 1.2 nM
Ibipinabant
CB1 , Ki: 7.8 nM
CB2 , Ki: 7943 nM
N-Arachidonyldopamine
CB1 , Ki: 250 nM
 
CB1R Allosteric modulator 2
hCB1-R
 
CB1R Allosteric modulator 1
hCB1-R
 
PM226  
CB2 , Ki: 13 nM
CB2 , EC50: 39 nM
NIDA-41020
CB1 , Ki: 4.1 nM
 
RVD-Hpα
CB1
 
MJ15
rCB1-R, Ki: 27.2 pM
rCB1-R, IC50: 118.9 pM
 
CBR Agonist-1
rCB1-R, Ki: 0.18 μM
hCB2-R, Ki: 1.22 μM
MRL-650
CB1 , IC50: 7.5 nM
CB2 , IC50: 4100 nM
CB1-IN-2
CB1 , IC50: 0.644 μM
 
Pregnenolone (Standard)
CB1
 
TM38837
CB1